1 Willey CJ, Blais JD, Hall AK, Krasa HB, et al. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2016 Jun (Epub ahead of print).
2 Schrier RW, Abebe KZ, Perrone RD, Torres VE, et al. Blood pressure in early autosomal dominant polycystic kidney disease.
N Engl J Med. 2014;371(24):2255–66.
3 Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.
4 Torres VE, Higarashi E, Devuyst O, et al. Effect of Tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol.
2016;11(5):803–11.
5 Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337–48.